You are here

  • Home
  • Archive
  • Volume 12, Issue 9
  • Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma

Article info

Article menu

Download PDFPDF

Gastroenterology and hepatology
Protocol
Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma

Authors

  • Bo Zhang Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Jinbo Yue Department of Abdominal Radiotherapy, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Xuetao Shi Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Kai Cui Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Lei Li Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Chengsheng Zhang Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Pengfei Sun Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Jingtao Zhong Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Zhongchao Li Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Lei Zhao Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Lei Zhao; drzhaolei{at}hotmail.com
View Full Text

Citation

Zhang B, Yue J, Shi X, et al
Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
BMJ Open 2022;12:e060955. doi: 10.1136/bmjopen-2022-060955

Publication history

  • Received January 10, 2022
  • Accepted September 1, 2022
  • First published September 17, 2022.
Online issue publication 
September 17, 2022
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.